BioChimPharm, the founding member of the Georgian Bio Pharmaceutical cluster, has completed EUR 6 million modernization project at the historic phage manufacturing facility in Tbilisi, which dates back to 1934. BioChimPharm is now producing life-saving, phage-based novel antibiotics with European precision and quality.

„We would like to express our heartfelt appreciation to our dear local and international partners (European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank and GITA) without whom this project would not have been possible. To honor their contributions, we proudly introduce the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing Phage Technology.

In today’s focus, we highlight the European Union and the FAO Georgia! We extend our sincere gratitude to the Food and Agriculture Organization (FAO), the FAO Georgia team, and the FAO Programme Coordinator, Javier Sanz Alvarez, for their remarkable support, under ENPARD III of the European Union, in the fight against AMR and the development of Phage Technology.

Please join us in celebrating this achievement by viewing the photos from our prize-giving ceremony, which showcase the dedication of our partners. Together, we are making significant strides in combating AMR and propelling Phage Technology. “ – Rati Golijashvili, General Manager of JSC Biochimpharm.

BioChimPharm, the founding member of the Georgian Bio Pharmaceutical cluster, has completed EUR 6 million modernization project at the historic phage manufacturing facility in Tbilisi, which dates back to 1934. BioChimPharm is now producing life-saving, phage-based novel antibiotics with European precision and quality.

„We would like to express our heartfelt appreciation to our dear local and international partners (European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank and GITA) without whom this project would not have been possible. To honor their contributions, we proudly introduce the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing Phage Technology.

In today’s focus, we highlight the EBRD! We extend our sincere gratitude to the European Bank for Reconstruction and Development, the EBRD Georgia team, and EBRD Regional Director, Catarina Bjorlin Hansen, for their remarkable support in the fight against AMR and the development of Phage Technology.

Please join us in celebrating this achievement by viewing the photos from our prize-giving ceremony, which showcase the dedication of our partners. Together, we are making significant strides in combating AMR and propelling Phage Technology. “ – Rati Golijashvili, General Manager of JSC Biochimpharm.

The Georgian pharmaceutical company "Neopharm" successfully passed the GDP (Good Distribution Practice) inspection and received the relevant standard certificate.

GDP is a globally recognized standard that helps pharmaceutical companies ensure the safe supply of medicines to the market.

A quality management system has been implemented in the "Neopharm" company, which ensures the supply of quality, effective and safe medicines at all stages of the distribution chain.

The pharmaceutical company "Neopharm" was founded in 1997 and has been part of the country's healthcare system for 25 years. The product portfolio consists of innovative, original prescription medicinal products, mostly made from herbal raw materials. Special technology ensures that the active pharmaceutical ingredient is obtained from plant raw materials in its natural state, which leads to the high efficiency of the final product and fewer side effects compared to synthetic substances.

Today, the company serially manufactures more than 100 products, including tinctures, extracts, syrups, herbal oils, capsules, tablets, ointments, eye drops, herbal substances, and cosmetics.

BioChimPharm has renovated the world`s oldest phage factory which was originally built in 1934.
The factory has been updated to comply with an internationally recognized standard EU GMP(Good Manufacturing Practice) guidelines.

Georgia has a rich history in the development of phage technology. 

Phages are tiny microorganisms that kill bacteria, in the modern world where we have a huge antibiotic-resistance problem, producing and providing access to phage therapy is essential. 

"Millions of people still do not have access to phages, leaving patients vulnerable to antibiotic-resistant infections," said Rati Golijashvili, the General Manager of BioChimPharm. "With this project, we are increasing our production capacity and export area, thus making bacteriophages available for millions of patients across the globe. The modernization of the manufacturing plant with high-tech infrastructure and production lines will enable BioChimPharm to scale up its production in compliance with internationally recognized manufacturing standards, to become more effective in the fight against resistant infections, and to overcome the global threat of antibiotic resistance."

BioChimPharm has nearly 100 years of experience in phage R&D and production, BioChimPharm's mission is to cut the overuse of antibiotics in the human and animal health industries and to overcome antibiotic-resistant infections globally. 

With the financial support of the European Union (EU), the United Nations Industrial Development Organization (UNIDO) organized a training series on the subject of Good Manufacturing Practice (GMP).

Trainings were held for The Georgian Pharmaceutical Cluster which unites the manufacturers of bacteriophages and herbal pharmaceuticals as well as support institutions.

Trainings were organized under the UN Joint Programme on Innovative Action for Private Sector Competitiveness in Georgia and are aimed to help Georgian pharmaceutical companies in raising the quality of production, increasing competitiveness, and implement international standards.

Get detailed information

October 27, 2022 – With the support of the European Union (EU), the United Nations Industrial Development Organization (UNIDO) organized an interactive, physical tour of the facilities of a leading Good Manufacturing Practice (GMP) compliant factory in Tbilisi.

The physical tour of the manufacturing site was planned as a complementary activity, enriching the overall experience received from participating in the broader training program on Good Manufacturing Practice (GMP). Therefore, the tour was delivered as a continuation of the series of trainings on the quality standard, ongoing since May 2022.

The tour was held for the Georgian biopharmaceutical cluster, which brings together both bacteriophage and herbal pharmaceutical companies and their supporting institutions and aims to help members develop competitiveness, increase sales and gain access to new markets.

The tour was organized under the UN Joint program on Innovative Action for Private Sector Competitiveness in Georgia. The program is funded by the European Union (EU) with a budget of USD 6 million and implemented by four UN agencies – the United Nations Development Programme (UNDP), the Food and Agriculture Organization of the United Nations (FAO), the United Nations Industrial Development Organization (UNIDO) and the International Organization for Migration (IOM).

The participants observed manufacturing facilities and the laboratory on site, reinforcing their theoretical knowledge gained during the trainings with practical observation. Two representatives were invited from 6 pharmaceutical companies to attend the tour.

The European Union and (UNIDO) will continue to support the Georgian biopharmaceutical cluster in the future in various directions.